Literature DB >> 31664687

Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more?

Camille Lenoir1, Myriam El Biali2, Christophe Luthy3, Olivier Grosgurin4, Jules Alexandre Desmeules2, Victoria Rollason2.   

Abstract

Background Proton pump inhibitors are among the most widely prescribed drugs in the world, but more than half of the indications for prescription are unjustified. The misuse of this therapeutic class has heavy consequences such as additional health costs, adverse drug reactions following long-term use and gastric acid rebound when the proton pump inhibitor is discontinued. Objective The overprescription of proton pump inhibitors is therefore becoming a public health problem, which led us to evaluate their use within the Geneva University Hospitals. Setting Patients hospitalized in two divisions of the department of internal medicine of the Geneva University Hospitals on a single day. Methods This is a register-based cross-sectional study and it collected data about the prescription pattern of proton pump inhibitors by consulting the electronic records of patients included. Main outcome measure To determine if the proton pump inhibitors prescription is made according to the market authorization and the available guidelines. Results Hundred-eighty patients were included. 54% of patients were on proton pump inhibitors, 29% of whom had their treatment initiated at hospital. Of the indications for treatment, 72% were not justified and 63% of the justified indications did not have an adequate dosage. Therefore, in all patients with a proton pump inhibitor at hospital, only 11% had a justified indication with an adequate dose. Finally, 87% of known home prescriptions were renewed on admission and among them, 71% did not have a justified or possibly justified indication according to the guidelines. Conclusion Indication for treatment inside the hospital was not justified in 72% of patients and only 11% had a justified indication with an adequate dosage. Precise guidelines with evidence-based indications and adequate daily doses would help to correctly prescribe proton pump inhibitors. Moreover, patients should benefit from a thorough evaluation of their treatment.

Entities:  

Keywords:  Drug-safety; Pharmacoepidemiology; Prescribing; Proton pump inhibitors; Public health; Switzerland; Tertiary care centers

Mesh:

Substances:

Year:  2019        PMID: 31664687     DOI: 10.1007/s11096-019-00929-w

Source DB:  PubMed          Journal:  Int J Clin Pharm


  5 in total

1.  Implementing a Multifaceted Intervention among Internal Medicine Residents with Audit and Educative Data Feedback Significantly Reduces Low-Value Care in Hospitalized Patients.

Authors:  Omar Kherad; Ezra Bottequin; Dorsaf Steiner; Axelle Alibert; Rodolphe Eurin; Hugo Bothorel
Journal:  J Clin Med       Date:  2022-04-26       Impact factor: 4.964

2.  Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults.

Authors:  Erik Puchon; Maria Goboova; Ivan Vano; Tomas Fazekas; Zuzana Javorova-Rihova; Magdalena Kuzelova
Journal:  Eur Geriatr Med       Date:  2020-08-17       Impact factor: 1.710

3.  Prescription Appropriateness of Drugs for Peptic Ulcer and Gastro-Esophageal Reflux Disease: Baseline Assessment in the LAPTOP-PPI Cluster Randomized Trial.

Authors:  Ilaria Ardoino; Manuela Casula; Giulia Molari; Sara Mucherino; Valentina Orlando; Enrica Menditto; Carlotta Franchi
Journal:  Front Pharmacol       Date:  2022-03-28       Impact factor: 5.810

4.  Assessment of proton-pump inhibitor use at a tertiary teaching hospital in Nigeria.

Authors:  Roland Nnaemeka Okoro; Kasim Abdullahi; Dauda Ayuba Dayar
Journal:  Med Access Point Care       Date:  2021-12-05

5.  Understanding the Patient PPI Journey: Results of a Survey on PPI Treatment Initiation and Patient Experience.

Authors:  Kate Plehhova; Natalie Paquette; James Gould; Cathal Coyle
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.